Improvement in neurophysiological parameters at ≤ 3 months · People with carpal tunnel syndrome on a waiting list for carpal tunnel release
1 finding from 1 review
CTS symptoms (Boston CTS questionnaire) ‐ long‐term improvement: > 3 monthsScale: 1 to 5, higher is worse · People with carpal tunnel syndrome on a waiting list for carpal tunnel release
1 finding from 1 review
Long‐term improvement in functional ability or health‐related quality of life (more than three months) · People with carpal tunnel syndrome on a waiting list for carpal tunnel release
1 finding from 1 review
Need for surgery · People with carpal tunnel syndrome on a waiting list for carpal tunnel release
It is very uncertain whether neurodynamic mobilisation changes need for surgery compared with no treatment (very low certainty).
1 finding from 1 review
Muscle strength · participants with Lambert‐Eaton myasthenic syndrome
1 finding from 1 review
Improvement in mean CMAP amplitude (mV) · participants with Lambert‐Eaton myasthenic syndrome
1 finding from 1 review
Adverse events · participants with Lambert‐Eaton myasthenic syndrome
1 finding from 1 review
Persistence of PHN among all subjects a numerical rating scale for pain1 · people at risk for postherpetic neuralgia
Vaccination leads to lower persistence of PHN among all subjects a numerical rating scale for… compared with placebo (high certainty).
1 finding from 1 review
Persistence of PHN among subjects developing herpes zoster a numerical rating scale for pain1 · people at risk for postherpetic neuralgia
Vaccination showed no clear difference in persistence of PHN among subjects developing herpes zoster a… compared with placebo (moderate certainty).
1 finding from 1 review
Death during whole · people at risk for postherpetic neuralgia
Vaccination showed no clear difference in deaths among all subjects during the whole study clinical compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events among subjects in the adverse event substudy clinical manifestations · people at risk for postherpetic neuralgia
Vaccination leads to higher serious adverse events among subjects in the adverse event substudy… compared with placebo (high certainty).
1 finding from 1 review
Change in ankle dorsiflexion range of motion Lidcome Template in degrees. Scale from: 0.36 to 31.28. · patients with patients with reduced ankle range of motion in neuromuscular disease
1 finding from 1 review
Intervention not reported
improvement in the maintenance of wakefulness test · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
1 finding from 1 review
Intervention not reported
improvement in the Epworth Sleepiness Score · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
1 finding from 1 review
Intervention not reported
improvement in multiple sleep latency test · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
1 finding from 1 review
Intervention not reported
quality of life scale ‐ mean improvement in total score of Short Form 36 · patients with hypersomnia (excessive daytime sleepiness) in myotonic dystrophy
1 finding from 1 review
Change in time taken for 6m comfortable walk (seconds) · patients with people with peripheral neuropathy
1 finding from 1 review
Change in isokinetic knee extension torque (Nm) · patients with people with peripheral neuropathy
1 finding from 1 review
Change in endurance at 80% MVC (seconds) · patients with people with peripheral neuropathy
1 finding from 1 review
Change in isokinetic knee flexion torque (Nm) · patients with people with peripheral neuropathy
1 finding from 1 review